SEARCH:   Advanced

Blood, 1 March 2008, Vol. 111, No. 5, pp. 2563-2572. Prepublished online as a Blood First Edition Paper on December 21, 2007; DOI 10.1182/blood-2007-10-116186. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2007-10-116186v1 111/5/2563    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pullarkat, V. Articles by Appelbaum, F. R. Search for Related Content PubMed PubMed Citation Articles by Pullarkat, V. Articles by Appelbaum, F. R. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study Vinod Pullarkat1, Marilyn L. Slovak2, Kenneth J. Kopecky3, Stephen J. Forman1, and Frederick R. Appelbaum4 1 Division of Hematology and Hematopoietic Cell Transplantation and 2 Department of Cytogenetics, City of Hope Comprehensive Cancer Center, Duarte, CA; 3 Southwest Oncology Group Statistical Center, Seattle, WA; and 4 Fred Hutchinson Cancer Research Center, University of Washington, Seattle We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic leukemia (ALL) patients 15 to 65 years of age enrolled in Southwest Oncology Group (SWOG)–9400 study. Evaluable cytogenetics or fluorescence in situ hybridization studies were available in 140 (70%) patients. Four karyotype categories (normal [n = 31, 22%], t(9;22)/BCR/ABL1 [n = 36, 26%], other unfavorable [–7, +8, or 11q23 rearrangement, n = 19, 13%], and miscellaneous [n = 54, 39%]) and the biologically and clinically relevant ALL ploidy subgroups were prospectively defined. Overall survival (OS) decreased significantly with increasing age (P = .009) and varied with karyotype category (P < .001). OS was worst for t(9;22)/BCR/ABL1 followed by other unfavorable karyotypes, with hazard ratios (HR) of 3.45 (95% confidence interval [CI], 1.88-6.31) and 2.14 (95% CI, 1.04-4.04), respectively, compared with normal diploid group. OS of the miscellaneous group was similar to that of the normal diploid group (HR = 0.82; 95% CI, 0.44-1.53). Relapse-free survival (RFS) was not significantly associated with age (P = .30) but was heterogeneous among karyotype categories (P < .001) primarily because of poor RFS in t(9;22)/BCR/ABL1 (HR = 3.49; 95% CI, 1.80-6.75) compared with the normal diploid group. After accounting for the variation among karyotype groups, age was not a significant prognostic factor for OS or RFS, highlighting cytogenetics as the most important prognostic factor in adult ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00002665 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. G. Laport, J. C. Alvarnas, J. M. Palmer, D. S. Snyder, M. L. Slovak, A. M. Cherry, R. M. Wong, R. S. Negrin, K. G. Blume, and S. J. Forman Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen Blood, August 1, 2008; 112(3): 903 - 909. [Abstract] [Full Text] [PDF] A. Fielding The Treatment of Adults with Acute Lymphoblastic Leukemia Hematology, January 1, 2008; 2008(1): 381 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020